Randomized, double-blind, parallel-group study to compare the pharmacokinetics, efficacy, safety, and immunogenicity of JPB898 (proposed nivolumab biosimilar) and US-licensed, EU-authorized Opdivo® in combination with Yervoy® in treatment-naïve participants with advanced (unresectable/metastatic) melanoma.
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: HEXAL AG
- Phase: III
- Execution start: 27/01/2025
- End of execution: 30/09/2027
- IP: JAVIER VALDIVIA BAUTISTA
